智通财经APP获悉，艾迪康控股(09860)尾盘涨近5%，截至发稿，涨2.77%，报7.06港元，成交额961.11万港元。
消息面上，艾迪康控股此前公布战略投资，向独立第三方收购元德维康(从事于血液诊断试剂的研发及生产)全部股权，代价1.79亿元人民币，将透过发行股支付。同时，集团内地ICL业务附属杭州艾迪康向独立第三方收购元德友勤(专门从事医学检验服务，拥有血液检测专业知识)全部股权，现金代价5000万人民币。
公开资料显示，元德友勤作为国内血液病诊断领域的标杆企业之一，多元化覆盖血液系统疾病，在白血病、淋巴瘤、多发性骨髓瘤、移植、出凝血领域拥有专业的诊断服务体系。而成立于2014年的元德维康，则是元德友勤的“前店后厂”配套。此次收购不仅标志着艾迪康加速布局特检赛道、深化血液疾病检测能力的关键一步，也为打造“检验-试剂-临床”一体化生态体系奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.